How do tumor cells respond to HDAC inhibition? (Q38817005)

6 September 2017

How do tumor cells respond to HDAC inhibition? (English)

1 reference

6 September 2017

Ricky W Johnstone

4

0 references

author name string

Andrea Newbold

series ordinal

1

1 reference

6 September 2017

Katrina J Falkenberg

series ordinal

2

1 reference

6 September 2017

H Miles Prince

series ordinal

3

1 reference

6 September 2017

language of work or name

English

0 references

publication date

26 April 2016

1 reference

6 September 2017

1 reference

6 September 2017

283

1 reference

6 September 2017

22

1 reference

6 September 2017

4032-4046

1 reference

Genetic syndromes caused by mutations in epigenetic genes

6 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Genetic and epigenetic regulators of pluripotency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Cancer epigenetics: from mechanism to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

21 January 2018

Epigenetics and oncology

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Histone deacetylase inhibitors in hematological malignancies and solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

New and emerging HDAC inhibitors for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Butyric acid, a potent inducer of erythroid differentiation in cultured erythroleukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Second generation hybrid polar compounds are potent inducers of transformed cell differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Lysine acetylation targets protein complexes and co-regulates major cellular functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Intrinsic and extrinsic apoptotic pathway signaling as determinants of histone deacetylase inhibitor antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Analysis of apoptosis regulatory genes altered by histone deacetylase inhibitors in chronic lymphocytic leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

HDAC8 and STAT3 repress BMF gene activity in colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Deciphering the molecular events necessary for synergistic tumor cell apoptosis mediated by the histone deacetylase inhibitor vorinostat and the BH3 mimetic ABT-737.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Physical association of HDAC1 and HDAC2 with p63 mediates transcriptional repression and tumor maintenance in squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Acetylation of FoxO1 activates Bim expression to induce apoptosis in response to histone deacetylase inhibitor depsipeptide treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Specific acetylation of p53 by HDAC inhibition prevents DNA damage-induced apoptosis in neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Sp1 acetylation is associated with loss of DNA binding at promoters associated with cell cycle arrest and cell death in a colon cell line.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

TSA suppresses miR-106b-93-25 cluster expression through downregulation of MYC and inhibits proliferation and induces apoptosis in human EMC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Elevation of c-FLIP in castrate-resistant prostate cancer antagonizes therapeutic response to androgen receptor-targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

HDAC inhibitors: roles of DNA damage and repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Collateral damage in cancer chemotherapy: oxidative stress in nontargeted tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Vorinostat induces reactive oxygen species and DNA damage in acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

HDAC inhibitors: a new radiosensitizer for non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

p53 Acetylation: Regulation and Consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Histone deacetylase inhibitors sensitize human non-small cell lung cancer cells to ionizing radiation through acetyl p53-mediated c-myc down-regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Defective cell cycle checkpoints as targets for anti-cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Degradation of cyclin A is regulated by acetylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

The role of p21(waf1/cip1) and p27(Kip1) in HDACi-mediated tumor cell death and cell cycle arrest in the Eμ-myc model of B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

p21(Waf1) is required for cellular senescence but not for cell cycle arrest induced by the HDAC inhibitor sodium butyrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

MicroRNA-31 is a transcriptional target of histone deacetylase inhibitors and a regulator of cellular senescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Oncogenic roles of Bmi1 and its therapeutic inhibition by histone deacetylase inhibitor in tongue cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Revisiting the differentiation paradigm in acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Role of the histone deacetylase complex in acute promyelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Histone deacetylase inhibitors induce the degradation of the t(8;21) fusion oncoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Differentiation of NUT midline carcinoma by epigenomic reprogramming

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

The HDAC inhibitor trichostatin A inhibits growth of small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Deacetylase inhibitors modulate proliferation and self-renewal properties of leukemic stem and progenitor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Suberoylanilide hydroxamic acid (SAHA) causes tumor growth slowdown and triggers autophagy in glioblastoma stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Novel histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in sarcoma cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

HDACs link the DNA damage response, processing of double-strand breaks and autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Apoptotic and autophagic cell death induced by histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Molecular mechanism of SAHA on regulation of autophagic cell death in tamoxifen-resistant MCF-7 breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Curbing autophagy and histone deacetylases to kill cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Vorinostat-induced autophagy switches from a death-promoting to a cytoprotective signal to drive acquired resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Histone deacetylase inhibitors induce autophagy through FOXO1-dependent pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Induction of autophagy does not alter the anti-tumor effects of HDAC inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Disruption of autophagy by the histone deacetylase inhibitor MGCD0103 and its therapeutic implication in B-cell chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Histone deacetylase 10 promotes autophagy-mediated cell survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Transcriptional modulation using HDACi depsipeptide promotes immune cell-mediated tumor destruction of murine B16 melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Chromatin-immune connections: regulation of MHC and other genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Epigenetic enhancement of antigen processing and presentation promotes immune recognition of tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Valproic acid upregulates NKG2D ligand expression through an ERK-dependent mechanism and potentially enhances NK cell-mediated lysis of myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Calreticulin exposure dictates the immunogenicity of cancer cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

An intact immune system is required for the anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Heat shock protein 90 as a drug target: some like it hot.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Drugging the HDAC6-HSP90 interplay in malignant cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Connectivity mapping identifies HDAC inhibitors for the treatment of t(4;11)-positive infant acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Therapeutic targeting of c-Myc in T-cell acute lymphoblastic leukemia, T-ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Histone deacetylase inhibitor romidepsin induces efficient tumor cell lysis via selective down-regulation of LMP1 and c-myc expression in EBV-positive diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Sin3b interacts with Myc and decreases Myc levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

BET bromodomain inhibition as a therapeutic strategy to target c-Myc

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Real-time imaging of histone H4K12-specific acetylation determines the modes of action of histone deacetylase and bromodomain inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13746

21 January 2018

Identifiers

DOI

10.1111/FEBS.13746

1 reference

6 September 2017

1 reference